Apoptotic markers in cancer

Clinical Biochemistry

Volumn 37, Issue 7, 2004, Pages 605-617

  Holdenrieder, S ^a   Stieber, P ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Apoptosis; Cancer; CD95; Cell death; CYFRA 21 1; Cytokeratins; Diagnosis; DNA; Monitoring; Nucleosomes; Prediction; Prognosis; sFas; Therapy; TPA; TPS; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CELL MARKER; CYTOKERATIN; CYTOKINE RECEPTOR; DNA FRAGMENT; FAS LIGAND; TUMOR MARKER;

ANALYTICAL PARAMETERS; APOPTOSIS; CANCER; CELL DEATH; CELL PROLIFERATION; CELL STRUCTURE; CYTOLOGY; HUMAN; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL DIVISION; HUMANS; MODELS, BIOLOGICAL; NECROSIS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 3042541642     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2004.05.003     Document Type: Review

References (182)

1. Majno G., Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 146:1995;3-15
2. Clarke P.G.H., Clarke S. Nineteenth century research on naturally occurring cell death and related phenomena. Anat. Embryol. 193:1996;81-99
3. Vogt C. Untersuchungen über die Entwicklungsgeschichte der Geburtshelferkröte (Alytes obstetricans). Solothurn 1842
4. Flemming W. Über die Bildung von Richtungsfiguren in Säugethiereiern beim Untergang Graaf'scher Follikel. Arch. Anat. Entwickl.gesch. 1885;221-244
5. Graeper L. Eine neue Anschauung über physiologische Zellausschaltung. Arch. Zellforsch. 12:1914;373-394
6. Gluecksmann A. Cell deaths in normal vertebrate ontogeny. Biol. Rev. 26:1951;59-86
7. Kerr J.F. Shrinkage necrosis: a distinct mode of cellular death. J. Pathol. 105:1971;13-20
8. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer. 26:1972;239-257
9. Arends M.J., Morris R.G., Wyllie A.H. Apoptosis. The role of the endonuclease. Am. J. Pathol. 136:1990;593-608
10. Kerr J.F., Winterford C.M., Harmon B.V. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 73:1994;2013-2026
11. Fadock V.A., Voelker D.R., Campbell P.A., Cohen J.J., Bratton D.L., Henson P.M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148:1992;2207-2216
12. Verhoven B., Schlegel R.A., Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J. Exp. Med. 182:1995;1597-1601
13. Hengartner M.O. Apoptosis: corraling the corpses. Cell. 104:2001;325-328
14. Wyllie A.H. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68:1980;251-306
15. Kanduc D., Mittelman A., Serpico R., Sinigaglia E., Sinha A.A., Natale C., et al. Cell death: apoptosis versus necrosis (review). Int. J. Oncol. 21:2002;165-170
16. Cotter T.G., Lennon S.V., Glynn J.G., Martin S.J. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. Anticancer Res. 10:1990;1153-1160
17. Darzynkiewicz Z., Juan G., Li X., Gorczyca W., Murakami T., Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry. 27:1997;1-20
18. Collins R.J., Harmon B.V., Gobe G.C., Kerr J.F. Internucleosomal DNA cleavage should not be the sole criterion for identifying apoptosis. Int. J. Radiat. Biol. 61:1992;451-453
19. Stewart B.W. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J. Natl. Cancer Inst. 86:1994;1286-1296
20. Cohen G.M., Sun X.M., Snowden R.T., Dinsdale D., Skilleter D.N. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem. J. 286:1992;331-334
21. Oberhammer F., Wilson J.W., Dive C., Morris I.D., Hickman J.A., Wakeling A.E., et al. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J. 12:1993;3679-3684
22. Klionsky D.J., Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science. 290:2000;1717-1721
23. Sperandio S., de Bell I., Bredesen D.E. An alternative, nonapoptotic form of programmed cell death. Proc. Natl. Acad. Sci. U. S. A. 97:2000;14376-14381
24. Leist M., Jäätelä M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev., Mol. Cell Biol. 2:2001;1-10
25. Lockshin R.A., Osborne B., Zakeri Z. Cell death in the third millennium. Cell Death Differ. 7:2000;2-7
26. Nicotera P., Leist M., Single B., Volbracht C. Execution of apoptosis: converging or diverging pathways? Biol. Chem. 380:1999;1035-1040
27. Richter C., Schweizer M., Cossarizza A., Franceschi C. Control of apoptosis by the cellular ATP level. FEBS Lett. 378:1996;107-110
28. Nicotera P., Leist M., Ferrando-May E. Intracellular ATP, a switch in the decision between apoptosis and necrosis. Toxicol Lett. 102-103:1998;139-142
29. Leist M., Single B., Castoldi A.F., Kuhnle S., Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. 185:1997;1481-1486
30. Matsuyama S., Llopis J., Deveraux Q.L., Tsien R.Y., Reed J.C. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat. Cell Biol. 2:2000;318-325
31. Leist M., Nicotera P. Calcium and neuronal death. Rev. Physiol. Biochem. Pharmacol. 132:1998;79-125
32. Cummings M.C., Winterford C.M., Walker N.I. Apoptosis. Am. J. Surg. Pathol. 21:1997;88-104
33. Prindull G. Apoptosis in the embryo and tumorigenesis. Eur. J. Cancer. 31:1995;116-123
34. Granville D.J., Carthy C.M., Hunt D.W.C., McManus B.M. Apoptosis: molecular aspects of cell death and disease. Lab. Invest. 78:1998;893-913
35. Krammer P.H. CD95 (APO-1/Fas)-mediated apoptosis: live and let die. Adv. Immunol. 71:1999;163-210
36. Ucker D.S. Death and dying in the immune system. Adv. Pharmacol. 41:1997;179-218
37. Desmouliere A., Badid C., Bochaton-Piallat M.L., Gabbiani G. Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. Int. J. Biochem. Cell Biol. 29:1997;19-30
38. Fadeel B., Orrenius S., Zhivotovsky B. Apoptosis in human disease: a new skin for the old ceremony? Biochem. Biophys. Res. Commun. 266:1999;699-717
39. Warner H.R., Hodes R.J., Pocinki K. What does cell death have to do with aging? J. Am. Geriatr. Soc. 45:1997;1140-1146
40. Robertson J.D., Fadeel B., Zhivotovsky B., Orrenius S. "Centennial" nobel conference on apoptosis and human disease. Cell Death Differ. 9:2002;468-475
41. Saikumar P., Dong Z., Mikhailov V., Denton M., Weinberg J.M., Venkatachalam M.A. Apoptosis: definition, mechanisms, and relevance to disease. Am. J. Med. 107:1999;489-506
42. Reed J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17:1999;2941-2953
43. Zoernig M., Hueber A.O., Baum W., Evan G. Apoptosis regulators and their role in tumorigenesis. Biochim. Biophys. Acta. 1551:2001;F1-F37
44. Aotake T., Lu C.D., Chiba Y., Muraoka R., Tanigawa N. Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis. Clin. Cancer Res. 5:1999;135-142
45. Braithwaite K.L., Rabbitts P.H. Multi-step evolution of lung cancer. Semin. Cancer Biol. 9:1999;255-265
46. Sionov R.V., Haupt Y. The cellular response to p53: the decision between life and death. Oncogene. 18:1999;6145-6157
47. Hengartner M.O. The biochemistry of apoptosis. Nature. 407:2000;770-776
48. Rich T., Allen R.L., Wyllie A.H. Defying death after DNA damage. Nature. 407:2000;777-783
49. Schaer P. Spontaneous DNA damage, genome instability, and cancer - When DNA replication escapes control. Cell. 104:2001;329-332
50. Savill J., Fadok V. Corpse clearance defines the meaning of cell death. Nature. 407:2000;784-788
51. Lichtenstein A.V., Melkonyan H.S., Tomei L.D., Umansky S.R. Circulating nucleic acids and apoptosis. Ann. N. Y. Acad. Sci. 945:2001;239-249
52. Stroun M., Maurice P., Vasioukhin V., Lyautey J., Lederrey C., Lefort F., et al. The origin and mechanism of circulating DNA. Ann. N. Y. Acad. Sci. 906:2000;161-168
53. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61:2001;1659-1665
54. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365
55. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science. 281:1998;1305-1308
56. Krammer P.H. CD95's deadly mission in the immune system. Nature. 407:2000;789-795
57. Slee E.A., Adrain C., Martin S.J. Serial killers: ordering caspase activation events in apoptosis. Cell Death Differ. 6:1999;1067-1074
58. Sartorius U., Schmitz I., Krammer P. Molecular mechanisms of death-receptor-mediated apoptosis. ChemBioChem. 2:2001;20-29
59. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1998;1675-1687
60. Joza N., Susin S.A., Daugas E., Stanford W.L., Cho S.K., Li C.Y.J., et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 410:2001;549-554
61. Nicholson D.W. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6:1999;1028-1042
62. Samali A., Zhivotovsky B., Jones D., Nagata S., Orrenius S. Apoptosis: cell death defined by caspase activation. Cell Death Differ. 6:1999;495-496
63. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 391:1998;43-50
64. Muzio M., Chinnaiyan A.M., Kischkel F.C., O'Rourke K., Shevchenko A., Ni J., et al. FLICE, a novel FADD-homologous ICE/ced-3-like protease, is recruited to the CD95 (Fas/Apo-1) death-inducing signaling complex. Cell. 85:1996;817-827
65. Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1313
66. Ekert P.G., Silke J., Vaux D.L. Caspase inhibitors. Cell Death Differ. 6:1999;1081-1086
67. Budihardjo I., Oliver H., Lutter M., Luo X., Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15:1999;269-290
68. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326
69. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat. Med. 3:1997;614-619
70. Reed J.C. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv. Pharmacol. 41:1997;501-532
71. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316
72. Jäättelä M. Escaping cell death: survival proteins in cancer. Exp. Cell Res. 248:1999;30-43
73. Deveraux Q.L., Stennicke H.R., Salvesen G.S., Reed J.C. Endogenous inhibitors of caspases. J. Clin. Immunol. 19:1999;388-398
74. Goyal L. Cell death inhibition: keeping caspases in check. Cell. 104:2001;805-808
75. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 102:2000;33-42
76. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 102:2000;43-53
77. Darzynkiewicz Z., Li X., Gong J. Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol. 41:1994;15-38
78. Mesner P.W., Kaufmann S.H. Methods utilized in the study of apoptosis. Adv. Pharmacol. 41:1997;57-87
79. Hentze H., Schoebel F., Lund S., Kehl M., Ertel W., Wendel A., et al. In vivo and in vitro evidence for extracellular caspase activity released from apoptotic cells. Biochem. Biophys. Res. Commun. 283:2001;1111-1117
80. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., Altieri D.C. Urine detection of survivin and diagnosis of bladder cancer. JAMA. 285:2001;324-328
81. Kushlinskii N.E., Britvin T.A., Abbasova S.G., Perevoshchikov A.G., Prorokov V.V., Kostanyan I.A., et al. Soluble Fas antigen in the serum of patients with colon cancer. Bull. Exp. Biol. Med. 131:2001;361-363
82. Liang Q.L., Pan D.C., Yin Z.M., Liu G.X., Yang Q., Xie J.R., et al. Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma. Ai Zheng. 21:2002;174-176
83. Peng Z., Tang H., Ling Y., Han G. Apoptosis and Fas system are significantly involved in the process of liver cirrhosis converting into hepatocellular carcinoma. J. Tongji Med. Univ. 21:2001;126-129
84. Sheen-Chen S.M., Chen H.S., Eng H.L., Chen W.J. Circulating soluble Fas in patients with breast cancer. World J. Surg. 27:2003;10-13
85. Ueno T., Toi M., Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin. Cancer Res. 5:1998;3529-3533
86. Konno R., Takano T., Sato S., Yajima A. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. Clin. Cancer Res. 6:2000;3576-3580
87. Hefler L., Mayerhofer K., Nardi A., Reinthaller A., Kainz C., Tempfer C. Serum soluble Fas levels in ovarian cancer. Obstet. Gynecol. 96:2000;65-69
88. Nonomura N., Nishimura K., Ono Y., Fukui T., Harada Y., Takaha N., et al. Soluble Fas in serum from patients with renal cell carcinoma. Urology. 55:2000;151-155
89. Kimura M., Tomita Y., Imai T., Saito T., Katagiri A., Tanikawa T., et al. Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients. Br. J. Cancer. 80:1999;1648-1651
90. Mouawad R., Khayat D., Soubrane C. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma. Melanoma Res. 10:2000;461-467
91. Ugurel S., Rappl G., Tilgen W., Reinhold U. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin. Cancer Res. 7:2001;1282-1286
92. Niitsu N., Sasaki K., Umeda M. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Leukemia. 13:1999;1434-1440
93. Osorio L.M., Aguilar-Santelises M., De Santiago A., Hachiya T., Mellstedt H., Jondal M. Increased serum levels of soluble Fas in progressive B-CLL. Eur. J. Haematol. 66:2001;342-346
94. Munker R., Younes A., Cabanillas F., Andreeff M. Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. Leuk. Lymphoma. 27:1997;517-521
95. Pignataro L., Arisi E., Sambataro G., Corsi M.M. Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment. J. Surg. Oncol. 83:2003;112-115
96. Hara T., Tsurumi H., Takemura M., Goto H., Yamada T., Sawada M., et al. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. Am. J. Hematol. 64:2000;257-261
97. Ichikura T., Majima T., Uchida T., Okura E., Ogawa T., Mochizuki H. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma. Oncol. Rep. 8:2001;311-314
98. Mizutani Y., Hongo F., Sato N., Ogawa O., Yoshida O., Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer. 92:2001;287-293
99. Bewick M., Conlon M., Parissenti A.M., Lee H., Zhang L., Gluck S., et al. Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J. Hematother. Stem Cell Res. 10:2001;759-768
100. Mizutani Y., Yoshida O., Ukimura O., Kawauchi A., Bonavida B., Miki T. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Cancer Biother. Radiopharm. 17:2002;563-567
101. Tsutsumi S., Kuwano H., Shimura T., Morinaga N., Mochiki E., Asao T. Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer. 89:2000;2560-2564
102. Kanda Y., Ara C., Chizuka A., Yamamoto R., Hamaki T., Suguro M., et al. Lack of correlation between clinical characteristics and serum soluble Fas ligand levels in patients with multiple myeloma. Leuk. Lymphoma. 40:2001;351-356
103. Buccheri G., Ferrigno D. Lung tumor markers of cytokeratin origin: an overview. Lung Cancer. 34:2001;S65-S69
104. Sheard M.A., Vojtesek B., Simickova M., Valik D. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J. Cell. Biochem. 85:2002;670-677
105. Wu F., Fujita J., Murota M., Li J.Q., Ishida T., Nishioka M., et al. CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7. Int. J. Oncol. 21:2002;441-445
106. Bodenmueller H., Ofenloch-Haehnle B., Lane E.B., Dessauer A., Bottger V., Donie F. Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21-1. Int. J. Biol. Markers. 9:1994;75-81
107. Stieber P., Hasholzner U., Bodenmueller H., Nagel D., Sunder-Plassmann L., Dienemann H., et al. CYFRA 21-1. A new marker in lung cancer. Cancer. 72:1993;707-713
108. Stieber P. Sensible use of tumor markers. J. Lab. Med. 25:2001;327-336
109. Leers M.P.G., Koelgen W., Bjoerklund V., Bergman T., Tribbick G., Persson B., et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 187:1999;567-572
110. Kramer G., Erdal H., Mertens H.J., Nap M., Mauermann J., Steiner G., et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 64:2004;1751-1756
111. Stieber P., Dienemann H., Hasholzner U., Muller C., Poley S., Hofmann K., et al. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur. J. Clin. Chem. Clin. Biochem. 31:1993;689-694
112. Stieber P., Dienemann H., Hasholzner U., Fabricius P.G., Schambeck C., Weinzierl M., et al. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int. J. Biol. Markers. 9:1994;82-88
113. Pujol J.L., Grenier J., Parrat E., Lehmann M., Lafontaine T., Quantin X., et al. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am. J. Respir. Crit. Care Med. 154:1996;725-733
114. Giovanella L., Ceriani L., Bandera M., Rimoldi R., Beghe B., Roncari G. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation. Q. J. Nucl. Med. 39:1995;285-289
115. Molina R., Filella X., Auge J.M., Fuentes R., Bover I., Rifa J., et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 24:2003;209-218
116. Pujol J.L., Grenier J., Daures J.P., Daver A., Pujol H., Michel F.B. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 53:1993;61-66
117. Schalhorn A., Fuerst H., Stieber P. Tumor markers in lung cancer. J. Lab. Med. 25:2001;353-361
118. Molina R., Agusti C., Filella X., Jo J., Joseph J., Gimenez N., et al. Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumour Biol. 15:1994;318-325
119. Giovanella L., Piantanida R., Ceriani L., Bandera M., Novario R., Bianchi L., et al. Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis. Int. J. Biol. Markers. 12:1997;22-26
120. Yazigi R., Castillo R., Aliste G., Garrido J., Opazo A., Prado S., et al. Cyfra 21-1 marker in carcinoma of the cervix. Int. J. Gynecol. Cancer. 10:2000;203-206
121. Nasu K., Etoh Y., Yoshimatsu J., Matsu T., Narahara H., Miyakawa I. Serum levels of cytokeratin 19 fragments in cervical cancer. Gynecol. Obstet. Invest. 42:1996;267-270
122. Ayude D., Gacio G., Paez de la Cadena M., Pallas E., Martinez-Zorzano V.S., de Carlos A., et al. Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma. Oncol. Rep. 10:2003;1345-1350
123. Deng Y.F., Chen P., Lin Y.Z., Le J.Z., Wu X.L., Yu M.Q., et al. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J. Laryngol. Otol. 117:2003;190-194
124. Tai C.J., Liu F.Y., Liang J.A., Yang S.N., Tsai M.H., Kao C.H. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma. Anticancer Res. 22:2002;3793-3796
125. Lee J.K., Hsieh J.F., Tsai S.C., Ho Y.J., Sun S.S., Kao C.H. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma. Ann. Otol. Rhinol. Laryngol. 110:2001;775-778
126. Brockmann J.G., St Nottberg H., Glodny B., Heinecke A., Senninger N.J. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin. Cancer Res. 6:2000;4249-4252
127. Nakata B., Chung Y.S., Kato Y., Ogawa M., Ogawa Y., Inui A., et al. Clinical significance of serum CYFRA 21-1 in gastric cancer. Br. J. Cancer. 73:1996;1529-1532
128. Kashihara T., Ohki A., Kobayashi T., Sato T., Nishizawa H., Ogawa K., et al. Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level. J. Gastroenterol. 33:1998;447-453
129. Uenishi T., Kubo S., Hirohashi K., Tanaka H., Shuto T., Yamamoto T., et al. Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br. J. Cancer. 88:2003;1894-1899
130. Yamamoto H., Miyake Y., Noura S., Ogawa M., Yasui M., Ikenaga M., et al. Tumor markers for colorectal cancer. Gan To Kagaku Ryoho. 28:2001;1299-1305
131. Giovanella L., Ceriani L., Giardina G., Bardelli D., Tanzi F., Garancini S. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Clin. Chem. Lab. Med. 40:2002;298-303
132. Rodriguez C.A., Cruz J.J., Martin T., Gomez A., Olaverri A., Hernandez M. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer. 95:2002;670-671
133. Nakata B., Ogawa Y., Ishikawa T., Ikeda K., Kato Y., Nishino H., et al. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer. 89:2000;1285-1290
134. Hasholzner U., Baumgartner L., Stieber P., Meier W., Hofmann K., Fateh-Moghadam A. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. Anticancer Res. 14:1994;2743-2746
135. Tramonti G., Ferdeghini M., Donadio C., Norpoth M., Annichiarico C., Bianchi R., et al. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia. Cancer Detect. Prev. 24:2000;86-90
136. Nakahama H., Tanaka Y., Fujita Y., Fujii M., Sugita M. CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients. Respirology. 3:1998;207-210
137. Pujol J.L., Boher J.M., Grenier J., Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer. 31:2001;221-231
138. Reinmuth N., Brandt B., Semik M., Kunze W.P., Achatzy R., Scheld H.H., et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer. 36:2002;265-270
139. Kasimir-Bauer S., Schleucher N., Weber R., Neumann R., Seeber S. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival. Oncol. Rep. 10:2003;475-482
140. Takei Y., Minato K., Tsuchiya S., Takise A., Nakano H., Ezawa K., et al. CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer. Oncology. 54:1997;43-47
141. Pujol J.L., Quantin X., Jacot W., Boher J.M., Grenier J., Lamy P.J. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer. 39:2003;131-138
142. Schouwink H., Korse C.M., Bonfrer J.M., Hart A.A., Baas P. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer. 25:1999;25-32
143. Tsuchiya Y., Onda M., Miyashita M., Sasajima K. Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus. Med. Oncol. 16:1999;31-37
144. Bonfrer J.M., Gaarenstroom K.N., Kenter G.G., Korse C.M., Hart A.A., Gallee M.P., et al. Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. Gynecol. Oncol. 55:1994;371-375
145. Ebert W., Muley T. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res. 19:1999;2669-2672
146. Vollmer R.T., Govindan R., Graziano S.L., Gamble G., Garst J., Kelley M.J., et al. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin. Cancer Res. 9:2003;1728-1733
147. Kuropkat C., Lippert B.M., Werner J.A. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck. Oncology. 63:2002;280-285
148. Pradier O., Hille A., Schmiberger H., Hess C.F. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1. Cancer Radiother. 6:2002;15-21
149. Pras E., Willemse P.H., Canrinus A.A., de Bruijn H.W., Sluiter W.J., ten Hoor K.A., et al. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Int. J. Radiat. Oncol. Biol. Phys. 52:2002;23-32
150. Ray P., Quantin X., Grenier J., Pujol J.L. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect. Prev. 22:1998;293-304
151. Muley T., Dienemann H., Ebert W. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. Anticancer Res. 23:2003;4085-4093
152. Sun S.S., Hsieh J.F., Tsai S.C., Ho Y.J., Lee J.K., Kao C.H. Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma. Am. J. Clin. Oncol. 23:2000;241-243
153. Yeh J.J., Liu F.Y., Hsu W.H., Wang J.J., Ho S.T., Kao A. Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection. Lung. 180:2002;273-279
154. Ueno T., Toi M., Biven K., Bando H., Ogawa T., Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur. J. Cancer. 39:2003;769-774
155. Rumore P., Muralidhar B., Lin M., Lai C., Steinman C.R. Hemodialysis as a model for studying endogenous plasma DNA: oligonucleosome-like structure and clearance. Clin. Exp. Immunol. 90:1992;56-62
156. Chan K.C.A., Zhang J., Chan A.T.C., Lei K.I.K., Leung S.F., Chan L.Y.S., et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 63:2003;2028-2032
157. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:1977;646-650
158. Shapiro B., Chakrabarty M., Cohn E.M., Leon S.A. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 51:1983;2116-2120
159. Maebo A. Plasma DNA level as a tumor marker in primary lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi. 28:1990;1085-1091
160. Fournie G.J., Courtin J.P., Laval F., Chale J.J., Pourrat J.P., Pujazon M.C., et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett. 91:1995;221-227
161. Kuroi K., Tanaka C., Toi M. Plasma nucleosome levels in node-negative breast cancer patients. Breast Cancer. 6:1999;361-364
162. Holdenrieder S., Stieber P., Foerg T., Kuehl M., Schulz L., Busch M., et al. Apoptosis in serum of patients with solid tumours. Anticancer Res. 19:1999;2721-2724
163. Lo Y.M.D., Chan L.Y., Lo K.W., Leung S.F., Zhang J., Chan A.T., et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 59:1999;1188-1191
164. Kuroi K., Tanaka C., Toi M. Clinical significance of plasma nucleosomes levels in cancer patients. Int. J. Oncol. 19:2001;143-148
165. Holdenrieder S., Stieber P., Bodenmueller H., Busch M., Fertig G., Fuerst H., et al. Nucleosomes in serum of patients with benign and malignant diseases. Int. J. Cancer. 95:2001;114-120
166. Holdenrieder S., Stieber P., Bodenmueller H., Fertig G., Fuerst H., Schmeller N., et al. Nucleosomes in serum as a marker for cell death. Clin. Chem. Lab. Med. 39:2001;596-605
167. Sozzi G., Conte D., Mariani L., Lo Vullo S., Roz L., Lombardo C., et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61:2001;4675-4678
168. Ziegler A., Zangemeister-Wittke U., Stahel R.A. Circulating DNA: a new diagnostic gold mine? Cancer Treat. Rev. 28:2002;255-271
169. Trejo-Becerril C., Perez-Cardenas E., Trevino-Cuevas H., Taja-Chayeb L., Garcia-Lopez P., Segura-Pacheco B., et al. Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int. J. Cancer. 104:2003;663-668
170. Anker P., Mulcahy H., Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int. J. Cancer. 103:2003;149-152
171. Sozzi G., Conte D., Leon M., Ciricione R., Roz L., Ratcliffe C., et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J. Clin. Oncol. 21:2003;3902-3908
172. Anker P., Stroun M. Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease. Leukemia. 15:2001;289-291
173. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349:2003;2042-2054
174. Sidransky D. Emerging molecular markers of cancer. Nat. Rev. Cancer. 2:2002;210-219
175. Andriani F., Conte D., Mastrangelo T., Leon M., Ratcliffe C., Roz L., et al. Detecting lung cancer in plasma with the use of multiple genetic markers. Int. J. Cancer. 108:2004;91-96
176. Lo Y.M.D., Chan A.T., Chan L.Y., Leung S.F., Lam C.W., Huang D.P., et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 60:2000;6878-6881
177. Silva J.M., Silva J., Sanchez A., Garcia J.M., Dominguez G., Provencio M., et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin. Cancer Res. 8:2002;3761-3766
178. Lei K.I., Chan L.Y., Chan W.Y., Johnson P.J., Lo Y.M.D. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin. Cancer Res. 8:2002;29-34
179. Holdenrieder S., Stieber P., Bodenmueller H., Busch M., v Pawel J., Schalhorn A., et al. Circulating nucleosomes in serum. Ann. N. Y. Acad. Sci. 945:2001;93-102
180. Lo Y.M.D., Chan L.Y., Chan A.T., Leung S.F., Lo K.W., Zhang J., et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 59:1999;5452-5455
181. Lo Y.M.D., Leung S.F., Chan L.Y., Chan A.T., Lo K.W., Johnson P.J., et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res. 60:2000;2351-2355
182. Holdenrieder S., Stieber P., v Pawel J., Raith H., Nagel D., Feldmann K., Seidel D. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non small cell lung cancer. Clin. Cancer Res. 2004;. [submitted for publication]